Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

1.

Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study.

Tuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A; HRRT [11C ]PBR28 study group, Collste K, Gallezot JD, Hillmer A, Huang Y, Höglund CO, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego CM, Stenkrona P, Rinne J, Matuskey D, Cervenka S.

Eur J Nucl Med Mol Imaging. 2019 Jul 30. doi: 10.1007/s00259-019-04403-7. [Epub ahead of print]

PMID:
31363804
2.

Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography.

Forsberg A, Lampa J, Estelius J, Cervenka S, Farde L, Halldin C, Lekander M, Olgart Höglund C, Kosek E.

J Neuroimmunol. 2019 Sep 15;334:577000. doi: 10.1016/j.jneuroim.2019.577000. Epub 2019 Jun 22.

PMID:
31260948
3.

Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain.

Yang KC, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ.

Neuropsychopharmacology. 2019 Sep;44(10):1706-1713. doi: 10.1038/s41386-019-0442-4. Epub 2019 Jun 19.

PMID:
31216565
4.

A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer.

Varrone A, Varnäs K, Jucaite A, Cselényi Z, Johnström P, Schou M, Vazquez-Romero A, Moein MM, Halldin C, Brown AP, Vishwanathan K, Farde L.

J Cereb Blood Flow Metab. 2019 Apr 20:271678X19843776. doi: 10.1177/0271678X19843776. [Epub ahead of print]

PMID:
31006308
5.

D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients.

Stenkrona P, Matheson GJ, Halldin C, Cervenka S, Farde L.

Int J Neuropsychopharmacol. 2019 Jul 1;22(7):415-425. doi: 10.1093/ijnp/pyz017.

6.

Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator.

Schou M, Ewing P, Cselenyi Z, Fridén M, Takano A, Halldin C, Farde L.

EJNMMI Res. 2019 Jan 29;9(1):9. doi: 10.1186/s13550-019-0479-8.

PMID:
30694407
7.

The development of a GPR44 targeting radioligand [11C]AZ12204657 for in vivo assessment of beta cell mass.

Jahan M, Johnström P, Selvaraju RK, Svedberg M, Winzell MS, Bernström J, Kingston L, Schou M, Jia Z, Skrtic S, Johansson L, Korsgren O, Farde L, Halldin C, Eriksson O.

EJNMMI Res. 2018 Dec 27;8(1):113. doi: 10.1186/s13550-018-0465-6.

8.

Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function.

Plavén-Sigray P, Matheson GJ, Cselényi Z, Jucaite A, Farde L, Cervenka S.

EJNMMI Res. 2018 Nov 29;8(1):102. doi: 10.1186/s13550-018-0455-8.

9.

Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study.

Venzi M, Tóth M, Häggkvist J, Bogstedt A, Rachalski A, Mattsson A, Frumento P, Farde L.

J Alzheimers Dis Rep. 2017 Nov 16;1(1):169-180. doi: 10.3233/ADR-170006.

10.

Serotonin 5-HT1A receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testing.

Griffioen G, Matheson GJ, Cervenka S, Farde L, Borg J.

PeerJ. 2018 Nov 16;6:e5790. doi: 10.7717/peerj.5790. eCollection 2018.

11.

GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models.

Horder J, Andersson M, Mendez MA, Singh N, Tangen Ä, Lundberg J, Gee A, Halldin C, Veronese M, Bölte S, Farde L, Sementa T, Cash D, Higgins K, Spain D, Turkheimer F, Mick I, Selvaraj S, Nutt DJ, Lingford-Hughes A, Howes OD, Murphy DG, Borg J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaam8434. doi: 10.1126/scitranslmed.aam8434.

12.

PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):367-375. doi: 10.1007/s00259-018-4161-6. Epub 2018 Oct 1.

13.

Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis.

Orhan F, Schwieler L, Fatouros-Bergman H, Malmqvist A, Cervenka S, Collste K, Flyckt L, Farde L, Sellgren CM, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Engberg G, Erhardt S.

Acta Psychiatr Scand. 2018 Nov;138(5):432-440. doi: 10.1111/acps.12944. Epub 2018 Aug 21.

PMID:
30132802
14.

[11C]SCH23390 binding to the D1-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis.

Stenkrona P, Matheson GJ, Cervenka S, Sigray PP, Halldin C, Farde L.

EJNMMI Res. 2018 Aug 2;8(1):74. doi: 10.1186/s13550-018-0416-2.

15.

Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain.

Yang KC, Takano A, Halldin C, Farde L, Finnema SJ.

Transl Psychiatry. 2018 Jul 16;8(1):132. doi: 10.1038/s41398-018-0178-7.

16.

The metabotropic glutamate receptor 5 radioligand [11C]AZD9272 identifies unique binding sites in primate brain.

Varnäs K, Juréus A, Finnema SJ, Johnström P, Raboisson P, Amini N, Takano A, Stepanov V, Halldin C, Farde L.

Neuropharmacology. 2018 Jun;135:455-463. doi: 10.1016/j.neuropharm.2018.03.039. Epub 2018 Mar 30.

17.

Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study.

Plavén-Sigray P, Matheson GJ, Gustavsson P, Stenkrona P, Halldin C, Farde L, Cervenka S.

PLoS One. 2018 Mar 15;13(3):e0193770. doi: 10.1371/journal.pone.0193770. eCollection 2018.

18.

Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders.

Farde L, Plavén-Sigray P, Borg J, Cervenka S.

Philos Trans R Soc Lond B Biol Sci. 2018 Apr 19;373(1744). pii: 20170156. doi: 10.1098/rstb.2017.0156. Review.

19.

Nigrostriatal dopamine transporter availability in early Parkinson's disease.

Fazio P, Svenningsson P, Cselényi Z, Halldin C, Farde L, Varrone A.

Mov Disord. 2018 Apr;33(4):592-599. doi: 10.1002/mds.27316. Epub 2018 Feb 13.

PMID:
29436751
20.

The MINDVIEW project: First results.

Benlloch JM, González AJ, Pani R, Preziosi E, Jackson C, Murphy J, Barberá J, Correcher C, Aussenhofer S, Gareis D, Visvikis D, Bert J, Langstrom B, Farde L, Toth M, Haggkvist J, Caixeta FV, Kullander K, Somlai-Schweiger I, Schwaiger M.

Eur Psychiatry. 2018 Apr;50:21-27. doi: 10.1016/j.eurpsy.2018.01.002. Epub 2018 Feb 2.

PMID:
29398564
21.

[11C]AZ10419096 - a full antagonist PET radioligand for imaging brain 5-HT1B receptors.

Lindberg A, Nag S, Schou M, Takano A, Matsumoto J, Amini N, Elmore CS, Farde L, Pike VW, Halldin C.

Nucl Med Biol. 2017 Nov;54:34-40. doi: 10.1016/j.nucmedbio.2017.07.007. Epub 2017 Jul 21.

PMID:
28950161
22.

Potential Effect of Prolonged Sevoflurane Anesthesia on the Kinetics of [11C]Raclopride in Non-human Primates.

Arakawa R, Farde L, Matsumoto J, Kanegawa N, Yakushev I, Yang KC, Takano A.

Mol Imaging Biol. 2018 Apr;20(2):183-187. doi: 10.1007/s11307-017-1120-8.

23.

Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.

Yang KC, Stepanov V, Martinsson S, Ettrup A, Takano A, Knudsen GM, Halldin C, Farde L, Finnema SJ.

Int J Neuropsychopharmacol. 2017 Sep 1;20(9):683-691. doi: 10.1093/ijnp/pyx051.

24.

Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data.

Matheson GJ, Plavén-Sigray P, Forsberg A, Varrone A, Farde L, Cervenka S.

EJNMMI Res. 2017 Dec;7(1):58. doi: 10.1186/s13550-017-0304-1. Epub 2017 Jul 21.

25.

Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390.

Matheson GJ, Stenkrona P, Cselényi Z, Plavén-Sigray P, Halldin C, Farde L, Cervenka S.

Neuroimage. 2017 Jul 15;155:344-353. doi: 10.1016/j.neuroimage.2017.04.031. Epub 2017 Apr 15.

26.

The immune response of the human brain to abdominal surgery.

Forsberg A, Cervenka S, Jonsson Fagerlund M, Rasmussen LS, Zetterberg H, Erlandsson Harris H, Stridh P, Christensson E, Granström A, Schening A, Dymmel K, Knave N, Terrando N, Maze M, Borg J, Varrone A, Halldin C, Blennow K, Farde L, Eriksson LI.

Ann Neurol. 2017 Apr;81(4):572-582. doi: 10.1002/ana.24909. Epub 2017 Apr 11.

27.

Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28.

Collste K, Plavén-Sigray P, Fatouros-Bergman H, Victorsson P, Schain M, Forsberg A, Amini N, Aeinehband S; Karolinska Schizophrenia Project (KaSP) consortium, Erhardt S, Halldin C, Flyckt L, Farde L, Cervenka S.

Mol Psychiatry. 2017 Jun;22(6):850-856. doi: 10.1038/mp.2016.247. Epub 2017 Feb 14.

PMID:
28194003
28.

GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans.

Jucaite A, Cselényi Z, Lappalainen J, McCarthy DJ, Lee CM, Nyberg S, Varnäs K, Stenkrona P, Halldin C, Cross A, Farde L.

Psychopharmacology (Berl). 2017 Feb;234(4):707-716. doi: 10.1007/s00213-016-4506-4. Epub 2016 Dec 24.

29.

Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain.

Yang KC, Stepanov V, Amini N, Martinsson S, Takano A, Nielsen J, Bundgaard C, Bang-Andersen B, Grimwood S, Halldin C, Farde L, Finnema SJ.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):308-320. doi: 10.1007/s00259-016-3544-9. Epub 2016 Nov 5.

30.

Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676.

Varnäs K, Juréus A, Johnström P, Ahlgren C, Schött P, Schou M, Gruber S, Jerning E, Malmborg J, Halldin C, Afzelius L, Farde L.

J Pharmacol Exp Ther. 2016 Sep;358(3):464-71. doi: 10.1124/jpet.116.234146. Epub 2016 Jul 11.

PMID:
27402278
31.

Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder.

Tiger M, Farde L, Rück C, Varrone A, Forsberg A, Lindefors N, Halldin C, Lundberg J.

Psychiatry Res Neuroimaging. 2016 Jul 30;253:36-42. doi: 10.1016/j.pscychresns.2016.04.016. Epub 2016 Apr 27.

32.

Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.

Sonni I, Fazio P, Schain M, Halldin C, Svenningsson P, Farde L, Varrone A.

J Nucl Med. 2016 Oct;57(10):1529-1534. Epub 2016 May 26.

33.

Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data.

Fazio P, Schain M, Varnäs K, Halldin C, Farde L, Varrone A.

Neuroimage. 2016 Jun;133:313-320. doi: 10.1016/j.neuroimage.2016.03.019. Epub 2016 Mar 17.

PMID:
26994829
34.

Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [18F]Lu AF10628.

Varnäs K, Finnema SJ, Stepanov V, Takano A, Tóth M, Svedberg M, Møller Nielsen S, Khanzhin NA, Juhl K, Bang-Andersen B, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2016 Aug 12;19(8). pii: pyw023. doi: 10.1093/ijnp/pyw023. Print 2016 Aug.

35.

Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain.

Borg J, Cervenka S, Kuja-Halkola R, Matheson GJ, Jönsson EG, Lichtenstein P, Henningsson S, Ichimiya T, Larsson H, Stenkrona P, Halldin C, Farde L.

Mol Psychiatry. 2016 Aug;21(8):1077-84. doi: 10.1038/mp.2015.147. Epub 2015 Oct 6.

PMID:
26821979
36.

In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects.

Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, Lekander M, Olgart Höglund C, Kosek E, Lampa J, Halldin C, Farde L, Varrone A, Cervenka S.

Brain Behav Immun. 2016 May;54:149-157. doi: 10.1016/j.bbi.2016.01.019. Epub 2016 Jan 25.

PMID:
26820224
37.

Discovery and Preclinical Validation of [(11)C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor.

Schou M, Varnäs K, Jureus A, Ahlgren C, Malmquist J, Häggkvist J, Tari L, Wesolowski SS, Throner SR, Brown DG, Nilsson M, Johnström P, Finnema SJ, Nakao R, Amini N, Takano A, Farde L.

ACS Chem Neurosci. 2016 Feb 17;7(2):177-84. doi: 10.1021/acschemneuro.5b00268. Epub 2015 Nov 30.

PMID:
26529287
38.

Distinct binding of amyloid imaging ligands to unique amyloid-β deposited in the presubiculum of Alzheimer's disease.

Ji B, Chen CJ, Bando K, Ashino H, Shiraishi H, Sano H, Kasahara H, Minamizawa T, Yamada K, Ono M, Zhang MR, Seki C, Farde L, Suhara T, Higuchi M.

J Neurochem. 2015 Dec;135(5):859-66. doi: 10.1111/jnc.13293. Epub 2015 Sep 17.

39.

Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects.

Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, Halldin C, Farde L, Cervenka S.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):173-183. doi: 10.1007/s00259-015-3149-8. Epub 2015 Aug 22.

PMID:
26293827
40.

Synthesis of ([(11)C]carbonyl)raclopride and a comparison with ([(11)C]methyl)raclopride in a monkey PET study.

Rahman O, Takano A, Amini N, Dahl K, Kanegawa N, Långström B, Farde L, Halldin C.

Nucl Med Biol. 2015 Nov;42(11):893-8. doi: 10.1016/j.nucmedbio.2015.07.003. Epub 2015 Jul 15.

PMID:
26272268
41.

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.

Jucaite A, Svenningsson P, Rinne JO, Cselényi Z, Varnäs K, Johnström P, Amini N, Kirjavainen A, Helin S, Minkwitz M, Kugler AR, Posener JA, Budd S, Halldin C, Varrone A, Farde L.

Brain. 2015 Sep;138(Pt 9):2687-700. doi: 10.1093/brain/awv184. Epub 2015 Jul 1.

PMID:
26137956
42.

Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain.

Fridén M, Wennerberg M, Antonsson M, Sandberg-Ställ M, Farde L, Schou M.

EJNMMI Res. 2014 Dec;4(1):50. doi: 10.1186/s13550-014-0050-6. Epub 2014 Sep 23.

43.

β-Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [¹¹C]AZD2184.

Mattsson P, Forsberg A, Persson J, Nyberg L, Nilsson LG, Halldin C, Farde L.

Eur J Nucl Med Mol Imaging. 2015 Sep;42(10):1507-11. doi: 10.1007/s00259-015-3103-9. Epub 2015 Jun 27.

PMID:
26115835
44.

Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.

Finnema SJ, Halldin C, Bang-Andersen B, Bundgaard C, Farde L.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4159-67. doi: 10.1007/s00213-015-3961-7. Epub 2015 May 17.

PMID:
25980484
45.

Application of cross-species PET imaging to assess neurotransmitter release in brain.

Finnema SJ, Scheinin M, Shahid M, Lehto J, Borroni E, Bang-Andersen B, Sallinen J, Wong E, Farde L, Halldin C, Grimwood S.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4129-57. doi: 10.1007/s00213-015-3938-6. Epub 2015 Apr 30. Review.

46.

5-HT1B receptor imaging and cognition: a positron emission tomography study in control subjects and Parkinson's disease patients.

Varrone A, Svenningsson P, Marklund P, Fatouros-Bergman H, Forsberg A, Halldin C, Nilsson LG, Farde L.

Synapse. 2015 Jul;69(7):365-74. doi: 10.1002/syn.21823. Epub 2015 May 25.

PMID:
25914348
47.

Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.

Cselényi Z, Farde L.

J Cereb Blood Flow Metab. 2015 Sep;35(9):1485-93. doi: 10.1038/jcbfm.2015.66. Epub 2015 Apr 15.

48.

Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates.

Schou M, Varnäs K, Lundquist S, Nakao R, Amini N, Takano A, Finnema SJ, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2015 Mar 26;18(10):pyv036. doi: 10.1093/ijnp/pyv036.

49.

Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.

Fazio P, Svenningsson P, Forsberg A, Jönsson EG, Amini N, Nakao R, Nag S, Halldin C, Farde L, Varrone A.

J Nucl Med. 2015 May;56(5):714-20. doi: 10.2967/jnumed.114.152421. Epub 2015 Mar 19.

50.

A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.

Hjorth S, Karlsson C, Jucaite A, Varnäs K, Wählby Hamrén U, Johnström P, Gulyás B, Donohue SR, Pike VW, Halldin C, Farde L.

Neuropharmacology. 2016 Feb;101:519-30. doi: 10.1016/j.neuropharm.2015.03.002. Epub 2015 Mar 17.

Supplemental Content

Support Center